Xcout Intel
ACES Diagnostics, Inc.
ACES Diagnostics, Inc. has developed LymeSeek, a multiplexed Luminex-based immunoassay designed to provide accurate diagnostic solutions for Lyme disease.
Subscribe to see ACES Diagnostics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ACES Diagnostics, Inc. at a glance
ACES Diagnostics, Inc. is a diagnostics company headquartered in United States. It has raised at least $4.4M across the 3 funding rounds on record. Its most recent funding round raised $400,000 in May 2026. Xcout tracks 12 named people at ACES Diagnostics, Inc., including Tammy Crawford (CEO).
ACES Diagnostics, Inc. leadership
- Tammy CrawfordCEO
- Glenn de SouzaChief Operating Officer
- Lisa StoneChief Financial Officer
- Jim KirkChief Development Officer
- Phillip StaffordChief Data Officer
- Tammy CrawfordFounder & Chief Executive Officer
6 more named people on record for ACES Diagnostics, Inc., with roles, board committees and tenure — see the full roster →
ACES Diagnostics, Inc. funding rounds
At least $4.4M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $400,000 | — | |
| Seed | $400,000 | 2 named | |
| SEC Form D filing | $3.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
ACES Diagnostics, Inc. competitors
A few of ACES Diagnostics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Aces Diagnostics has developed LymeSeek, a multiplexed Luminex-based immunoassay designed to detect Lyme disease. The blood test is intended to improve early detection across all stages of the disease, though it is not yet FDA-approved or commercially available.
LumiraDx Ltd provides diagnostic products, specifically offering rapid microfluidic immunofluorescence assays such as the SARS-CoV-2 Ag test. These in vitro diagnostic tools are designed for near-patient and clinical settings to deliver rapid, lab-comparable health results.
Inflammatix, Inc. is a molecular diagnostics and biotechnology research company headquartered in Sunnyvale, California. It develops rapid point-of-care host-response diagnostic tests for suspected acute infections or sepsis.
CyVek is a biotechnology and medical device company established in 2010 and headquartered in Wallingford, Connecticut. The company developed the CyPlex immunoassay technology, which integrates a microfluidic cartridge platform for measuring biological markers in the life sciences sector.
Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.
StabiLux Biosciences develops high-brightness dye technology utilizing boron nitride nanoparticles for biomedical applications. The company's platform supports antibodies, RNA, and proteins to help researchers detect biomarkers for early cancer detection, drug discovery, mRNA vaccines, and immunology.
Get ACES Diagnostics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ACES Diagnostics, Inc. in Xcout Intel
- 12 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access